SMARCA4 (switch/sucrose non-fermentable-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4)-deficient thoracic tumours have shown poor prognosis in clinical settings. Although the optimal treatment for SMARCA4-deficient thoracic tumours remains unclear, existing studies indicate a favourable response of these tumours to immune checkpoint inhibitors (ICIs). However, there are no reports of fatality in SMARCA4-deficient small-cell lung carcinoma (SCLC) with hyper-progressive disease (HPD) upon treatment with ICIs. Herein, we report a patient with SMARCA4-deficient SCLC who had HPD after the first ICI treatment. A 35-year-old man was treated with nivolumab, subsequent to cytotoxic chemotherapy. A week after nivolumab initiation, chest computed tomography revealed marked increase in pleural effusion in the right lung and chest wall dissemination of the tumour, which concur with the definition of HPD. This is the first study to report the occurrence of HPD after treatment with ICIs in a patient with SMARCA4-deficient SCLC. Analysis of additional data is necessary to determine the optimal treatment for these patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506996 | PMC |
| http://dx.doi.org/10.1002/rcr2.667 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma.
NPJ Precis Oncol
September 2024
Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Hyper progressive disease (HPD) is a paradoxical phenomenon characterized by accelerated tumor growth following treatment with immune checkpoint inhibitors. However, the pathogenic causality and its predictor remain unknown. We herein report a fatal case of HPD in a 50-year-old man with metastatic bladder cancer.
View Article and Find Full Text PDFPrognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study.
Oncol Lett
September 2024
Department of Oncology, Nanjing Jinling Hospital of Nanjing University, Nanjing, Jiangsu 210012, P.R. China.
Advanced liver cancer is the most common malignant tumor in the elderly, but it also occurs in young people in areas where hepatitis B virus is prevalent. The aim of the present study was to assess the efficacy of systemic antitumor therapy in young patients with advanced liver cancer and investigate the influencing factors. The baseline demographic and clinical data of 38 young patients (≤35 years old) with liver cancer were collected as group A and that of 79 elderly patients (≥55 years old) with liver cancer were collected as group B.
View Article and Find Full Text PDFRapid tumor progression complicated with liver abscess in a patient with gastric cancer receiving nivolumab therapy.
Int Cancer Conf J
April 2024
Department of Gastroenterology, Tokyo Bay Urayasu Ichikawa Medical Center, 3-4-32 Toudaijima, Urayasu, Chiba 279-0001 Japan.
Immune checkpoint inhibitors have been approved for treating various cancer types. However, several studies reported rapid tumor progression, a condition known as hyperprogressive disease, after treatment with immune checkpoint inhibitors. We present the case of a 73-year-old man diagnosed with recurrent gastric cancer with liver and lymph node metastases detected in the presence of obstructive jaundice.
View Article and Find Full Text PDFIncidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.
Liver Cancer
February 2024
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Article Synopsis
- The study investigates the effectiveness of PD-1/PD-L1 signaling blockade in treating immune evading hepatocellular carcinoma (HCC) and highlights the issue of unexpected tumor growth known as hyper progressive disease (HPD).
- A cohort of 198 patients with unresectable HCC was analyzed, comparing those receiving anti-PD-1/PD-L1 monotherapy and those receiving combination therapies with VEGF and anti-CTLA-4 antibodies.
- Results showed a higher HPD rate in the monotherapy group (10.3%) compared to the combination therapy groups, with the anti-CTLA-4 combination showing no increase in HPD frequency, indicating better outcomes with combination treatments.
Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study.
Cancer Cell Int
September 2023
School of Medicine, Nankai University, 94 Weijin Road, Nankai, Tianjin, China.
Background: Hyper progressive disease (HPD) describes the phenomenon that patients can't benefit from immunotherapy but cause rapid tumor progression. HPD is a particular phenomenon in immunotherapy but lacks prediction methods. Our study aims to screen the factors that may forecast HPD and provide a predictive model for risky stratifying.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!